131 related articles for article (PubMed ID: 33006987)
1. Cost-effectiveness of sofosbuvir in hepatitis C genotype 1 infection in Germany: A reanalysis of published results.
Gandjour A
PLoS One; 2020; 15(10):e0236543. PubMed ID: 33006987
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of Interferon-free therapy for Hepatitis C in Germany--an application of the efficiency frontier approach.
Gissel C; Götz G; Mahlich J; Repp H
BMC Infect Dis; 2015 Jul; 15():297. PubMed ID: 26223310
[TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness Modelling of Sofosbuvir-Containing Regimens for Chronic Genotype 5 Hepatitis C Virus Infection in South Africa.
Fraser I; Burger J; Lubbe M; Dranitsaris G; Sonderup M; Stander T
Pharmacoeconomics; 2016 Apr; 34(4):403-17. PubMed ID: 26666639
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection.
Saab S; Gordon SC; Park H; Sulkowski M; Ahmed A; Younossi Z
Aliment Pharmacol Ther; 2014 Sep; 40(6):657-75. PubMed ID: 25065960
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of sofosbuvir plus ribavirin therapy for hepatitis C virus genotype 2 infection in South Korea.
Chung W; Kim KA; Jang ES; Ki M; Choi HY; Jeong SH
J Gastroenterol Hepatol; 2019 Apr; 34(4):776-783. PubMed ID: 30462841
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of Oral Regimens for Adolescents With Chronic Hepatitis C Virus Infection.
Zhou H; Lu Y; Wu B; Che D
Pediatr Infect Dis J; 2020 Jun; 39(6):e59-e65. PubMed ID: 32345829
[TBL] [Abstract][Full Text] [Related]
7. Daclatasvir for the Treatment of Chronic Hepatitis C: A Critique of the Clinical and Economic Evidence.
Llewellyn A; Faria R; Woods B; Simmonds M; Lomas J; Woolacott N; Griffin S
Pharmacoeconomics; 2016 Oct; 34(10):981-92. PubMed ID: 27278217
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus.
Najafzadeh M; Andersson K; Shrank WH; Krumme AA; Matlin OS; Brennan T; Avorn J; Choudhry NK
Ann Intern Med; 2015 Mar; 162(6):407-19. PubMed ID: 25775313
[TBL] [Abstract][Full Text] [Related]
9. The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection.
Linas BP; Barter DM; Morgan JR; Pho MT; Leff JA; Schackman BR; Horsburgh CR; Assoumou SA; Salomon JA; Weinstein MC; Freedberg KA; Kim AY
Ann Intern Med; 2015 May; 162(9):619-29. PubMed ID: 25820703
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US.
Zhang S; Bastian ND; Griffin PM
BMC Gastroenterol; 2015 Aug; 15():98. PubMed ID: 26239358
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of the highly effective direct-acting antivirals in the treatment of chronic hepatitis C in Hong Kong.
Lo AO; Chan HL; Wong VW; Wong GL
J Gastroenterol Hepatol; 2017 May; 32(5):1071-1078. PubMed ID: 28449343
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of daclatasvir plus sofosbuvir-based regimen for treatment of hepatitis C virus genotype 3 infection in Canada.
Moshyk A; Martel MJ; Tahami Monfared AA; Goeree R
J Med Econ; 2016; 19(2):181-92. PubMed ID: 26453248
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of sofosbuvir plus ribavirin with or without pegylated interferon for the treatment of chronic hepatitis C in Italy.
Cure S; Guerra I; Cammà C; Craxì A; Carosi G
J Med Econ; 2015; 18(9):678-90. PubMed ID: 25891129
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and cost-effectiveness of initial combination therapy with interferon/peginterferon plus ribavirin in patients with chronic hepatitis C in Germany: a health technology assessment commissioned by the German Federal Ministry of Health and Social Security.
Siebert U; Sroczynski G; ;
Int J Technol Assess Health Care; 2005; 21(1):55-65. PubMed ID: 15736515
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of boceprevir co-administration versus pegylated interferon-α2b and ribavirin only for patients with hepatitis C genotype 1 in Singapore.
Dan YY; Ferrante SA; Elbasha EH; Hsu TY
Antivir Ther; 2015; 20(2):209-16. PubMed ID: 25105844
[TBL] [Abstract][Full Text] [Related]
16. A cost utility analysis of simeprevir used with peginterferon + ribavirin in the management of genotype 1 hepatitis C virus infection, from the perspective of the UK National Health Service.
Westerhout K; Treur M; Mehnert A; Pascoe K; Ladha I; Belsey J
J Med Econ; 2015; 18(10):838-49. PubMed ID: 25903830
[TBL] [Abstract][Full Text] [Related]
17. [Cost-effectiveness analysis of sofosbuvir, peginterferon and ribavirin in patients with chronic hepatitis C: Early treatment in the initial stage of fibrosis vs. delayed treatment in advanced fibrosis].
Buti M; Domínguez-Hernández R; Oyagüez I; Casado MÁ
Gastroenterol Hepatol; 2016; 39(7):449-57. PubMed ID: 27084669
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of sofosbuvir compared to current standard treatment in Swiss patients with chronic hepatitis C.
Pfeil AM; Reich O; Guerra IM; Cure S; Negro F; Müllhaupt B; Lavanchy D; Schwenkglenks M
PLoS One; 2015; 10(5):e0126984. PubMed ID: 25974722
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in Italy.
Restelli U; Alberti A; Lazzarin A; Bonfanti M; Nappi C; Croce D
Eur J Health Econ; 2018 Jan; 19(1):37-44. PubMed ID: 28008546
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States.
Chhatwal J; Kanwal F; Roberts MS; Dunn MA
Ann Intern Med; 2015 Mar; 162(6):397-406. PubMed ID: 25775312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
